Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

ROSELAND, N.J., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (“Emisphere” or the “Company”) today announced that it has entered into a definitive agreement with Novo Nordisk A/S (“Novo Nordisk”), whereby Novo Nordisk will acquire Emisphere, on a cash-free, debt-free basis, for $1.35 billion in cash. The consideration to be paid per share will depend on the amount of cash and debt at closing, but the Company currently estimates it to be approximately $7.82 per share based on approximately 170.9 million fully diluted shares outstanding. This price represents a premium of approximately 17% over the volume-weighted average Emisphere share price for the five trading days ending on November 5, 2020.

Novo Nordisk to Acquire Emisphere Technologies for $1.35 Billion

Danish diabetes drug maker Novo Nordisk will acquire U.S. Emisphere Technologies, which specialises in developing orally administered versions of drugs, in a deal totalling $1.8 billion, it said on Friday.

Denmark's Novo Nordisk to buy Emisphere Technologies in $1.8 billion deal

Novo Nordisk (NVO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Novo Nordisk (NVO) Catches Eye: Stock Jumps 7.2%

Bagsværd, Denmark, 4 November 2020 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Trading in Novo Nordisk shares by board members, executives and associated persons on 4 November 2020

Novo Nordisk A/S purchases B shares worth DKK 2,913 million from Novo Holdings A/S under the 2020 share repurchase programme

Novo Nordisk A/S (NVO) CEO Lars Fruergaard Jorgensen on Q3 2020 Results - Earnings Call Transcript

Novo Nordisk (NVO) misses earnings and sales estimates in the third quarter of 2020.

Novo Nordisk's (NVO) Q3 Earnings Beat Estimates, Sales Miss

Novo Nordisk (ETR: NOVC) said on Friday that its net profit in the fiscal third quarter came in better than expected. The company highlighted that patients in Europe and the United States stockpiled roughly £241.77 million worth of medicines in the fiscal first quarter amidst the ongoing COVID-19 crisis that has so far infected more than 45 million people worldwide and caused over 1.18 million deaths.

Novo Nordisk's sales jump 2.1% to £3.74 billion in the fiscal third quarter

30 October 2020 - Financial report for the period 1 January 2020 to 30 September 2020

Novo Nordisk's operating profit increased by 6% in Danish kroner and by 7% at constant exchange rates (CER) in the first nine months of 2020

Biogen

Illumina

ResMed

In light of coronavirus cases increasing both domestically and internationally, four health care companies with strong business quality are Biogen Inc. (NASDAQ:BIIB), Novo Nordisk A/S (NYSE:NVO), ResMed Inc. (NYSE:RMD) and Illumina Inc. (NASDAQ:ILMN) according to the All-in-One Screener, a Premium feature of GuruFocus.

4 Health Care Companies With Strong Business Quality

British American Tobacco

Nestle SA

Novartis

Roche Holding AG

SAP SE

Sanofi

Unilever

Vanguard FTSE Developed Markets ETF

Leading wealth managers including BlackRock, Merrill Lynch and Putnam are advising their clients to invest in foreign stocks to take advantage of better values overseas. And the market's best European stocks are one such store of value-priced diversification.

10 Best European Stocks for an Income-Rich Recovery

Novo Nordisk (NVO) raises 2020 sales and operating profit outlook at constant exchange rates.

Novo Nordisk Raises Sales & Operating Profit Outlook for 2020

Bagsværd, Denmark, 8 October 2020 – Novo Nordisk today announced that the full-year sales and operating profit outlook at constant exchange rates (CER) has been raised.                    

Novo Nordisk raises sales and operating profit outlook for 2020

With sales growing 8% and net profits growing 12% in the first half of 2020, Novo Nordisk could report solid numbers.

Revisiting Novo Nordisk

The company's value chain may have been shaken by Covid-19 but it wasn't broken, so Novo Nordisk stock holders should stay invested. The post Hold Novo Nordisk Shares for Consistent International Growth appeared first on InvestorPlace.

Hold Novo Nordisk Shares for Consistent International Growth

AmerisourceBergen

Chemed

Neogen

As the world grapples with an unprecedented coronavirus pandemic, five health care stocks that have outperformed the Standard & Poor's 500 Index by at least 5% in the year to date are AmerisourceBergen Corp. (NYSE:ABC), Chemed Corp. (NYSE:CHE), Neogen Corp. (NASDAQ:NEOG), Novo Nordisk A/S (NYSE:NVO) and ResMed Inc. (NYSE:RMD) according to the All-in-One Screener, a Premium feature of GuruFocus.

5 Health Care Stocks Outperforming the S&P 500

WASHINGTON, Sept. 10, 2020 /PRNewswire/ -- The American College of Cardiology, in partnership with Novo Nordisk Inc.

ACC, Novo Nordisk Partner to Improve Cardiovascular Disease Management in Patients with Type 2 Diabetes

Apple

HCA Healthcare

Johnson & Johnson

Stryker

Teladoc

Ventas

The healthcare industry has historically delivered market-beating returns. And the current pandemic has created new opportunities in the sector.

The Top 7 Healthcare Stocks You Should Be Watching

AstraZeneca

Other pharmas working on stem cells to repair degenerative brain damage

AstraZeneca, Novo Pursuing Alzheimer's as Metabolic Disease

SEATTLE, Aug. 24, 2020 /PRNewswire/ -- UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY In re NOVO NORDISK SECURITIES LITIGATION Master File No.

Notice of Pendency of Class Action Involving all Persons and Entities who Purchased the American Depository Receipts of Novo Nordisk from February 3, 2015 through February 2, 2017

Novo Nordisk shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
The post Novo Nordisk Getting Closer To Key Technical Measure appeared first on Investor's Business Daily.

Novo Nordisk Getting Closer To Key Technical Measure

The Danish multinational offers an exciting growth opportunity.

Novo Nordisk in the expanding market of diabetes care

Novo Nordisk: Long-Term Growth By CV Risk Factor Reduction

Novo Nordisk (NVO) resumes the phase III studies on concizumabin in hemophilia A and B patients regardless of inhibitor status.

Novo Nordisk (NVO) Resumes Phase III Hemophilia Studies

DexCom

Tandem Diabetes Care

DexCom, Tandem Diabetes, and Novo Nordisk have plenty of momentum and growth ahead, making them excellent buys this month.

3 Top Diabetes Stocks to Buy in August

News for Novo Nordisk Stock (NVO)